Story perspectives

Gotistobart Extends Median Survival to 18.5 Months in NSCLC Trial

By Drooid · Sep 14, 2026, 11:24 PM UTC · How we work

Summary

Story summary

BioNTech and OncoC4 announced in South Korea that gotistobart extended median overall survival to 18.5 months versus 10.0 months.
The PRESERVE-003 Phase 3 stage 1 trial randomized 87 metastatic squamous NSCLC patients to gotistobart or docetaxel.
Grade >= 3 treatment-related adverse events occurred in 44.4% of gotistobart patients and 48.8% of docetaxel patients.
Gotistobart holds Fast Track and orphan designations from the U.S. FDA and breakthrough status from China’s NMPA.

1 of 1

Story summary

BioNTech and OncoC4 announced in South Korea that gotistobart extended median overall survival to 18.5 months versus 10.0 months.
The PRESERVE-003 Phase 3 stage 1 trial randomized 87 metastatic squamous NSCLC patients to gotistobart or docetaxel.
Grade >= 3 treatment-related adverse events occurred in 44.4% of gotistobart patients and 48.8% of docetaxel patients.
Gotistobart holds Fast Track and orphan designations from the U.S. FDA and breakthrough status from China’s NMPA.